Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499154 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2CES1IDO1ALPLTDO2 | |
| SCHEMBL499359 | 0.89 | CES1 (0.35) | SMN1; SMN2CES1IDO1ALPLTDO2 | |
| SCHEMBL499623 | 0.88 | TGM2 (0.35) | IDO1 | |
| SCHEMBL499622 | 0.88 | TGM2 (0.35) | IDO1 | |
| SCHEMBL499008 | 0.84 | CES1 (0.35) | SMN1; SMN2CES1ALPL | |
| SCHEMBL499413 | 0.76 | REN (0.44) | — | |
| SCHEMBL499412 | 0.76 | REN (0.44) | — | |
| SCHEMBL499411 | 0.76 | REN (0.44) | — | |
| SCHEMBL499563 | 0.76 | CES1 (0.35) | CES1IDO1TDO2 | |
| SCHEMBL499562 | 0.76 | CES1 (0.35) | CES1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | SMN1; SMN2 3254/4885CES1 275/4885IDO1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.